NCT01703702

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 641 (actual)
• Sponsor: Avid Radiopharmaceuticals · Industry
• Sex: All
• Age: 50 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to determine the effectiveness of florbetapir (18F) in changing patient management and to evaluate the association between scan status and cognitive decline.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	florbetapir (18F)	Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration

Timeline

• Start date: 2012-10-01
• Primary completion: 2015-04-01
• Completion: 2015-04-01
• First posted: 2012-10-10
• Last updated: 2016-08-17
• Results posted: 2016-08-17

Locations

57 sites across 3 countries: United States, France, Italy